Tokyo Tape
Sign in

Santen Pharmaceutical

4536.TTSE PRIMEPharmaceutical
Filed as SANTEN PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Key numbers · FY ended 2026-03
Revenue¥291.6bn-2.8% YoYOperating income¥47.8bn+2.0% YoYNet income (owners)¥37.4bn+3.1% YoYTotal assets¥423.0bn+3.4% YoYEPS (basic)¥114.04+9.7% YoY

Full financial history and reports →

Stock price4536 · View chart ↗

Open the price chart on TradingView.

Latest filings
Tue, Oct 27 · JST1 filing
10:41MATERIALSanten Pharmaceutical · Change in major shareholder
Mon, Oct 26 · JST1 filing
15:285% STAKESanten Pharmaceutical · Silchester International Investors LLP · 9.23% → 10.25%+1.02pp
Tue, Oct 8 · JST1 filing
16:48MATERIALSanten Pharmaceutical · Change in parent company or specified subsidiary

All filings →

Major holders (5%+) · 2
HolderStakeChangeFiled
Silchester International Investors LLP10.25%+1.02pp2026-10-26
Nomura Asset Management Co., Ltd.5.26%—2024-06-06

Each holder's own ratio from its most recent large-shareholding report.